Hashimoto's thyroiditis
Conditions
Interventions
Intervention Group:Qinggan Sanjie Xiaoying granule
Control Group:Placebo
Sponsors
Sun Simiao Hospital of Beijing University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. 34 IU/mL < TPOAb < 600 IU/mL; 2. TGAb < 4000 IU/mL; 3. TRAB(-); 4. Thyroid ultrasound showed diffuse enlargement or heterogeneous echo; 5. Aged 18-70 years; 6. Thyroid hormones (FT3, FT4, T3, T4) were within the reference range; 7. Elevated levels of thyroid stimulating hormone (subclinical hypothyroidism); 8. Drug washout period: no clinical trial, immune preparation and Chinese medicine were conducted within 3 months before enrollment; 9. No drugs affecting thyroid hormone metabolism, including corticosteroids, preparations containing vitamins or trace elements, amiodarone a Interferons, lithium preparations, antidepressants or antipsychotics, etc; 10. Did not participate in other clinical studies; 11. Signed the informed consent to participate in this study.
Exclusion criteria
Exclusion criteria: 1. With non-diabetic kidney disease; 2. Severe infection, anemia, or electrolyte imbalance in the previous four weeks; 3. Oliguria, anuria, severe edema, massive pleural or peritoneal effusion; 4. Use of corticosteroids or immunosuppressants in the previous three months; 5. Severe cardiac, cerebral, hepatic, or hemorrhagic diseases, including stroke, transient ischemic attack, significant neurological dysfunction remaining after stroke ,myocardial infarction, unstable angina, ischemic heart disease with coronary artery bypass or PCI surgery, congestive heart failure (cardiac function class III-IV, NYHA rating),hepatic inadequacy with aspartate transaminase(AST) or alanine aminotransferase (ALT)levels more than twice the normal upper limit, severe thrombocytopenia (PLT <10×10^9/L, abnormal coagulation, or active gastrointestinal bleeding; 6. Tuberculosis or mental disorders; 7. Pregnancy or lactation; 8. Participation in other clinical studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Estimated glomerular filtration rate (eGFR); | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence rate of eGFR fell by 20%;Adipocyte fatty acid-binding protein(A-FABP);Lipid metabolomics;urinary albumin-to-creatinine ratio (UACR);TCM syndrome integral score;quality of life; | — |
Countries
China
Contacts
Public ContactZhiguo Ding
Sun Simiao Hospital of Beijing University of Traditional Chinese Medicine
Outcome results
None listed